Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tohru Funahashi

Showing results (31-40 of 328) with videos related to

Pageof 33
Sort By:
Medical Molecular Morphology|June 19, 2007
Pathophysiological significance of adiponectinMakoto Nishida, Tohru Funahashi, Iichiro Shimomura
Journal of Diabetes and Its Complications|March 2, 2002
Molecular mechanism of vascular disease in metabolic syndrome XYuji Matsuzawa, Tohru Funahashi, Tadashi Nakamura
Handbook of Experimental Pharmacology|December 20, 2008
Role of aquaporin-7 and aquaporin-9 in glycerol metabolism; involvement in obesityNorikazu Maeda, Toshiyuki Hibuse, Tohru Funahashi
Nature Clinical Practice. Endocrinology & Metabolism|October 15, 2008
Metabolic impact of adipose and hepatic glycerol channels aquaporin 7 and aquaporin 9Norikazu Maeda, Tohru Funahashi, Iichiro Shimomura
Diabetes Research and Clinical Practice|December 14, 2011
Three-month treatment with pioglitazone reduces circulating levels of S100A8/A9 (MRP8/14) complex, a biomarker of inflammation, without changes in body mass index, in type 2 diabetics with abdominal obesityHideaki Nakatsuji, Ken Kishida, Tohru Funahashi, et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine|July 20, 2011
[Aquaporin adipose (AQPap)]Norikazu Maeda, Toshiyuki Hibuse, Tohru Funahashi, et al.
Annals of Medicine|May 27, 2011
Visceral adiposity as a target for the management of the metabolic syndromeKen Kishida, Tohru Funahashi, Yuji Matsuzawa, et al.
Atherosclerosis|June 15, 2010
Three-month treatment with pioglitazone reduces circulating levels of thiobarbituric acid-reacting substances, a marker of reactive oxidative stress, without change in body mass index, in Japanese patients with type 2 diabetesHideaki Nakatsuji, Ken Kishida, Tohru Funahashi, et al.
Hormone Research|December 13, 2003
Importance of adipocytokines in obesity-related diseasesYuji Matsuzawa, Iichiro Shimomura, Shinji Kihara, et al.
Atherosclerosis|November 16, 2019
Adiponectin, a unique adipocyte-derived factor beyond hormonesNorikazu Maeda, Tohru Funahashi, Yuji Matsuzawa, et al.
Pageof 33

Showing results (31-40 of 328) with videos related to

Sort By:
Pageof 33
Medical Molecular Morphology|June 19, 2007
Pathophysiological significance of adiponectinMakoto Nishida, Tohru Funahashi, Iichiro Shimomura
Journal of Diabetes and Its Complications|March 2, 2002
Molecular mechanism of vascular disease in metabolic syndrome XYuji Matsuzawa, Tohru Funahashi, Tadashi Nakamura
Handbook of Experimental Pharmacology|December 20, 2008
Role of aquaporin-7 and aquaporin-9 in glycerol metabolism; involvement in obesityNorikazu Maeda, Toshiyuki Hibuse, Tohru Funahashi
Nature Clinical Practice. Endocrinology & Metabolism|October 15, 2008
Metabolic impact of adipose and hepatic glycerol channels aquaporin 7 and aquaporin 9Norikazu Maeda, Tohru Funahashi, Iichiro Shimomura
Diabetes Research and Clinical Practice|December 14, 2011
Three-month treatment with pioglitazone reduces circulating levels of S100A8/A9 (MRP8/14) complex, a biomarker of inflammation, without changes in body mass index, in type 2 diabetics with abdominal obesityHideaki Nakatsuji, Ken Kishida, Tohru Funahashi, et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine|July 20, 2011
[Aquaporin adipose (AQPap)]Norikazu Maeda, Toshiyuki Hibuse, Tohru Funahashi, et al.
Annals of Medicine|May 27, 2011
Visceral adiposity as a target for the management of the metabolic syndromeKen Kishida, Tohru Funahashi, Yuji Matsuzawa, et al.
Atherosclerosis|June 15, 2010
Three-month treatment with pioglitazone reduces circulating levels of thiobarbituric acid-reacting substances, a marker of reactive oxidative stress, without change in body mass index, in Japanese patients with type 2 diabetesHideaki Nakatsuji, Ken Kishida, Tohru Funahashi, et al.
Hormone Research|December 13, 2003
Importance of adipocytokines in obesity-related diseasesYuji Matsuzawa, Iichiro Shimomura, Shinji Kihara, et al.
Atherosclerosis|November 16, 2019
Adiponectin, a unique adipocyte-derived factor beyond hormonesNorikazu Maeda, Tohru Funahashi, Yuji Matsuzawa, et al.
Pageof 33